JP4961084B2 - Ｆａｂｉ阻害剤 - Google Patents

Ｆａｂｉ阻害剤 Download PDF

Info

Publication number
JP4961084B2
JP4961084B2 JP2001529444A JP2001529444A JP4961084B2 JP 4961084 B2 JP4961084 B2 JP 4961084B2 JP 2001529444 A JP2001529444 A JP 2001529444A JP 2001529444 A JP2001529444 A JP 2001529444A JP 4961084 B2 JP4961084 B2 JP 4961084B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
amino
phenyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001529444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511415A (ja
JP2003511415A5 (https=
Inventor
ウィリアム・エイチ・ミラー
ケネス・エイ・ニューランダー
マーク・エイ・シーフェルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affinium Pharmaceuticals Inc
Original Assignee
Affinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affinium Pharmaceuticals Inc filed Critical Affinium Pharmaceuticals Inc
Publication of JP2003511415A publication Critical patent/JP2003511415A/ja
Publication of JP2003511415A5 publication Critical patent/JP2003511415A5/ja
Application granted granted Critical
Publication of JP4961084B2 publication Critical patent/JP4961084B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Semiconductor Lasers (AREA)
JP2001529444A 1999-10-08 2000-10-06 Ｆａｂｉ阻害剤 Expired - Fee Related JP4961084B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15852999P 1999-10-08 1999-10-08
US60/158,529 1999-10-08
PCT/US2000/027591 WO2001026654A1 (en) 1999-10-08 2000-10-06 Fab i inhibitors

Publications (3)

Publication Number Publication Date
JP2003511415A JP2003511415A (ja) 2003-03-25
JP2003511415A5 JP2003511415A5 (https=) 2012-03-22
JP4961084B2 true JP4961084B2 (ja) 2012-06-27

Family

ID=22568552

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001529444A Expired - Fee Related JP4961084B2 (ja) 1999-10-08 2000-10-06 Ｆａｂｉ阻害剤

Country Status (8)

Country Link
EP (1) EP1225895B1 (https=)
JP (1) JP4961084B2 (https=)
AT (1) ATE294578T1 (https=)
AU (1) AU1192501A (https=)
CO (1) CO5251401A1 (https=)
DE (1) DE60019954T2 (https=)
HK (1) HK1049610A1 (https=)
WO (1) WO2001026654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CO5251397A1 (es) * 1999-10-08 2003-02-28 Smithkline Beecham Corp Inhibidores de fab i
ATE285821T1 (de) 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
CA2444597A1 (en) 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1575951B1 (en) * 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
DE602004016831D1 (de) * 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
CN101203504B (zh) * 2005-05-03 2012-11-14 兰贝克赛实验室有限公司 抗微生物剂
DK1879877T3 (da) 2005-05-03 2013-04-15 Ranbaxy Lab Ltd Antimikrobielle midler
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP2742047B1 (en) 2011-08-10 2021-05-12 Janssen Sciences Ireland Unlimited Company Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US9394295B2 (en) 2011-08-10 2016-07-19 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
CN104981466B (zh) 2012-08-10 2019-06-14 爱尔兰詹森科学公司 抗细菌化合物
MX363480B (es) 2012-08-10 2019-03-22 Janssen Sciences Ireland Uc Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US5932743A (en) * 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds

Also Published As

Publication number Publication date
HK1049610A1 (zh) 2003-05-23
DE60019954D1 (en) 2005-06-09
WO2001026654A1 (en) 2001-04-19
JP2003511415A (ja) 2003-03-25
DE60019954T2 (de) 2006-02-23
EP1225895A1 (en) 2002-07-31
ATE294578T1 (de) 2005-05-15
EP1225895B1 (en) 2005-05-04
AU1192501A (en) 2001-04-23
CO5251401A1 (es) 2003-02-28
EP1225895A4 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
JP4961084B2 (ja) Ｆａｂｉ阻害剤
JP4831907B2 (ja) ＦａｂＩ阻害剤
JP4733836B2 (ja) 抗菌化合物
JP4803935B2 (ja) Ｆａｂｉ阻害剤
JP4647791B2 (ja) ＦａｂＩ阻害剤
US6762201B1 (en) Fab I inhibitors
US6730684B1 (en) Fab I inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20041207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110913

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120228

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120326

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150330

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees